我如何治疗慢性炎症性脱线性多性神经病 Podcast
1Neurosciences Institute, Atrium Health Wake Forest Baptist, A Facility of Carolinas Medical Center, Charlotte, NC, USA. udesai@wakehealth.edu.
Neurology and therapy
|June 26, 2023
概括
更新的2021年欧洲神经学会/外围神经学会指南简化了诊断慢性炎症性脱髓性多神经病变 (CIDP). 该指南有助于区分CIDP变体和自身免疫结节病,改善治疗和患者的治疗结果.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床实践指南 临床实践指南
背景情况:
- 慢性炎症性脱髓性多神经病 (CIDP) 是一种免疫媒介的神经病,具有多种症状,往往导致诊断延迟.
- 正确诊断CIDP是具有挑战性的,因为症状与其他神经病变重叠.
研究的目的:
- 讨论更新的欧洲神经科学院/外围神经学会 (EAN/PNS) 2021年关于CIDP诊断和治疗的指南的影响.
- 探索新指南如何帮助区分CIDP与其变体和自身免疫结节病.
主要方法:
- 对CIDP诊断和治疗的EAN/PNS 2021指南的审查.
- 讨论患者病例研究,以说明指南的应用.
- 一位神经病学家对临床实践整合的专家见解.
主要成果:
- 2021年指南为诊断典型的CIDP,CIDP变体和自身免疫结节病提供了明确的标准.
- 自免疫结节病现在与CIDP不同,突出了这些患者治疗指南中的差距.
- 在治疗建议中包括皮下免疫球蛋白 (SCIG) 与当前的临床实践一致.
结论:
- 更新的指南促进了更简单,更一致的CIDP分类,导致更快的诊断和更好的治疗反应.
- 提高诊断准确度会对患者的预后和临床结果产生积极影响.
- 该指南为优化对CIDP患者的管理提供了有价值的见解.
相关概念视频
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13
Peripheral Artery Disease IV: Nursing Management
13
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
13
Chronic Pancreatitis II: Collaborative Care
116
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
116
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607


